Lung Toxicity - Restrictive lung disease

Reviews
Shared by: Amna Khan
Stats
views:
124
rating:
not rated
reviews:
0
posted:
4/21/2008
language:
pages:
0
Lung Toxicity - 4A: Restrictive lung disease • restrictive lung disease – chronic lung disease characterized by progressive stiffening of lung parenchyma – arising from chronic localized inflammation followed by pulmonary fibrosis – scarring and destruction of alveoli and terminal airways --> loss of vital capacity • localized inflammation – principally parenchymal tissue (nodular, arborized, „ground glass‟ on Xrays) • alveoli + adjacent respiratory bronchioles (RB) and membranous bronchioles (MB) – no large airway involvement (no bronchial thickening on Xrays) • pulmonary fibrosis – localized chronic inflammation and scarring in alveoli and terminal airways – pathological formation of fibrous scar tissue (mainly collagen fibres) – fibrosis in alveolar walls (parenchymal disease) • interstitial fibrosis (alveolar interstitium) – alveolar capillary destruction F2007 HLTH 350 Lecture 4A 1 Lung abnormalities in restrictive lung disease • reduced lung compliance – interstitial fibrosis -- middle layer of alveolar wall thickens and scars – abnormal stiffness in alveolar walls – greater effort required to inflate lungs • reduction in total lung (alveolar) capacity (TLC) – progressive reduction in forced vital capacity (FVC) in spirometric tests • loss of functional alveoli (and some small airways) • reduced gas exchange – due to interstitial thickening and scarring of alveolar walls – destruction of alveolar capillaries • alveolar capillary block and cor pulmonale (advanced disease) F2007 HLTH 350 Lecture 4A 2 Spirometry testing in restrictive lung diseases • reduced FVC – reduced capacity for lungs to fill with air at inspiration – major diagnostic feature of restrictive lung diseases • FEV1 may be unaffected or moderately reduced – depends on extent of small airways disease • FEV1/FVC ratio may be in ‘normal’ range or elevated – opposite pattern to obstructive lung diseases F2007 HLTH 350 Lecture 4A 3 Classes of interstitial lung disease F2007 HLTH 350 Lecture 4A 4 Mineral dust disease - pneumoconiosis • pneumoconiosis (‘dust in the lungs’ -Grk.) – – – – – – – – accumulation of large quantities of mineral dust in lungs chronic restrictive lung disease long latency (years or decades) variable in occurrence and severity between individuals and groups „hard rock‟ mining -- gold, uranium, nickel, zinc, other metal ores quarrying of granite and other igneous rocks tunneling and other excavations coal mining • dusty occupations long associated with chronic lung disease • degenerative lung disease after years of exposure – “miner‟s consumption” -- combination of lung degeneration assoc with TB • may overlap with some obstructive lung pathology, esp. in smokers – need to distinguish clinically between pneumoconiosis vs. COPD F2007 HLTH 350 Lecture 4A 5 Workplace mineral dusts and metals associated with pneumoconiosis F2007 HLTH 350 Lecture 4A 6 Sources of variability in mineral dust diseases • lung infection – often made workers more vulnerable to tuberculosis – still prevalent in developing countries e.g. South African gold miners – is it pneumoconiosis or is it TB? • smoking history – most miners have a history of past or current cigarette smoking – is it pneumoconiosis or is it COPD? • particle factors – size, shape, hygroscopicity, persistence in lung, etc. – respirable fraction • defines what fraction of inhalable dust (<10 uM) is respirable dust (<5 or 2.5 uM) • RF = PM5/PM10 (or PM2.5 / PM10) • only respirable fraction of mineral dusts are deemed hazardous – example: WTC dust Sept 11 RF = .02 ( i.e. 2%) F2007 HLTH 350 Lecture 4A 7 Classes of mineral dust • „benign’ (inert) dusts – most common mineral dusts appear harmless to lungs – appear to cause minimal or no lung inflammation – considered as “nuisance dusts‟ • fibrogenic (toxic) dusts – relatively small exposures cause severe pulmonary fibrosis – can induce severe parenchymal inflammation – only a few mineral dusts are fibrogenic -- silica, asbestos • variable (mixed) dusts – coal dusts (varying widely in silica content) • PNOC – Particulates Not Otherwise Classified – replaces obsolete terms such as nuisance dusts, benign dusts etc. F2007 HLTH 350 Lecture 4A 8 PNOC - Particulates Not Otherwise Classified • American Conference of Government Industrial Hygienists (ACGIH) – devised term in 1994; also used by many government regulatory bodies • PNOR - Particulates Not Otherwise Regulated (U.S. OSHA) • refers to occupational dusts with no evidence of specific toxic effects – architecture of air spaces (alveoli) remains intact – collagen (scar tissue) not formed to a significant extent – tissue (inflammatory) reaction is potentially reversible • identified in the past as ‘nuisance dusts’ or ‘inert particulates’ – misleading term which suggests that these materials are harmless – all materials are potentially toxic at sufficiently high doses • ‘pulmonary overload’ concept – inert particulates may cause harm by overloading lung tissues • ‘generic particle’ concept – inert particulates can contribute collectively to pulmonary overload F2007 HLTH 350 Lecture 4A 9 • ACGIH has introduced a TLV occupational exposure limit for PNOC – ACGIH TLV exposure limits are intended as a guideline (not legally binding) PNOCs have their own occupational exposure limits • PNOC definition -- dusts defined as PNOC if they fulfill all 3 criteria: – insoluble mineral dusts (excludes biological dusts, soluble chemicals) – inhalable dusts that contain <1% crystalline silica and no asbestos – dusts with no other TLV value to control exposure • TLV - threshold limit value – maximum allowable air exposure for hazardous substances in workplace air – commonly based on time-weighted average exposure level (TWAEL) of worker • 40 hours per week for 50 weeks per year over working lifetime (approx 30 years) • ACGIH TLV values for PNOC (1994) – 10 mg/m3 for inhalable particulate – 3 mg/m3 for respirable particulate • ACGIH’s most recent TLV’s are legally binding in Ontario (TWAEL) F2007 HLTH 350 Lecture 4A 10

Related docs
RESTRICTIVE LUNG DISEASE
Views: 134  |  Downloads: 9
Lung Toxicity - Lung Defenses
Views: 92  |  Downloads: 1
Lung Cancer
Views: 81  |  Downloads: 10
Interstitial Lung Disease
Views: 125  |  Downloads: 17
Lung - Pathology
Views: 149  |  Downloads: 23
Lung
Views: 2  |  Downloads: 0
Lung Cancer
Views: 7  |  Downloads: 0
Other docs by Amna Khan
Wandering spleen
Views: 819  |  Downloads: 34
Variation of Spleen Size in College Age Athletes
Views: 617  |  Downloads: 2
THYMIC TUMORS - General Thoracic Surgery
Views: 640  |  Downloads: 32
Thymic malignancies and other mediastinal tumors
Views: 892  |  Downloads: 57
TCVM Food Therapy for Gastrointestinal Disorders
Views: 623  |  Downloads: 13
Stomach and spleen
Views: 1509  |  Downloads: 47
Spleen Injuries Contusion and Laceration
Views: 2675  |  Downloads: 36
Spleen - Ultrasound Technique.
Views: 920  |  Downloads: 44
She has tuberculosis of peripheral lymph nodes
Views: 531  |  Downloads: 9
Platelet Disorders in Companion Animals
Views: 434  |  Downloads: 5
Osseous Tissue and Bone Structure
Views: 1538  |  Downloads: 29